Clinical Research Directory
Browse clinical research sites, groups, and studies.
Liraglutide Treatment in Obese Infertile PCOS Women
Sponsor: Peking University Third Hospital
Summary
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility. Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.
Key Details
Gender
FEMALE
Age Range
20 Years - 40 Years
Study Type
INTERVENTIONAL
Enrollment
890
Start Date
2025-05-22
Completion Date
2029-12-31
Last Updated
2025-05-29
Healthy Volunteers
No
Conditions
Interventions
Liraglutide and metformin
Liraglutide 3.0 mg or maximum tolerable dose/day × 12 weeks and metformin 1500 mg/day until pregnancy.
Metformin
Metformin 1500 mg/day until pregnancy
Locations (3)
Peking University Third Hospital
Beijing, Beijing Municipality, China
Beijing Obstetrics and Gynecology Hospital
Beijing, China
Haidian District Maternal and Child Health Care Hospital
Beijing, China